Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: June 27, 2017
What are the generic sources for clopidogrel bisulfate and what is the scope of clopidogrel bisulfate freedom to operate?
Clopidogrel bisulfate is the generic ingredient in two branded drugs marketed by Allied Pharma Inc, Actavis Totowa, Gate Pharms, Dr Reddys Labs Ltd, Accord Hlthcare, Teva Pharms, Macleods Pharms Ltd, Sun Pharm Inds, Sanofi Aventis Us, Aurobindo Pharma Ltd, Torrent Pharms Ltd, Amneal Pharms, Cspc Ouyi Pharm Co, Mylan Pharms Inc, Sciegen Pharms Inc, Wockhardt Ltd, Dr Reddys Labs Inc, Apotex Inc, Zydus Pharms Usa Inc, Sun Pharma Global, and Teva, and is included in twenty-one NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.| Tradenames: | 2 |
| Patents: | 3 |
| Applicants: | 21 |
| NDAs: | 21 |
| Drug Master File Entries: see list | 53 |
| Suppliers / Packagers: see list | 50 |
| Bulk Api Vendors: see list | 75 |
| Clinical Trials: see list | 630 |
| Patent Applications: see list | 3,240 |
| Therapeutic Class: | Blood Products/Modifiers/ Volume Expanders |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | clopidogrel bisulfate at DailyMed |
| Drug Class | P2Y12 Platelet Inhibitor |
| Mechanism of Action | P2Y12 Receptor Antagonists Cytochrome P450 2C8 Inhibitors |
| Physiological Effect | Decreased Platelet Aggregation |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Totowa | CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 090307-001 | May 28, 2013 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Dr Reddys Labs Inc | CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 076273-001 | Jan 14, 2008 | AB | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-002 | Sep 20, 2007 | AB | RX | Yes | Yes | 6,429,210*PED | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Accord Hlthcare | CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 202925-001 | Mar 27, 2013 | AB | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
Macleods Pharms Ltd | CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 202928-001 | Feb 10, 2014 | AB | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-001 | Nov 17, 1997 | 4,529,596 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-001 | Nov 17, 1997 | 5,576,328*PED | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-002 | Sep 20, 2007 | 4,847,265*PED | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-001 | Nov 17, 1997 | 4,847,265*PED | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portugal | 1087976 | ► Subscribe | |||||||||||||||||||||||||||
| Algeria | 2817 | ► Subscribe | |||||||||||||||||||||||||||
| Colombia | 5040084 | ► Subscribe | |||||||||||||||||||||||||||
| Saudi Arabia | 1433 | ► Subscribe | |||||||||||||||||||||||||||
| France | 2779726 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90035-0 98910359 | Sweden | ► Subscribe | PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715 | ||||||||||||||||||||||||||
| C/GB99/001 | United Kingdom | ► Subscribe | PRODUCT NAME: CLOPIDOGREL HYDROGEN SULPHATE, THE DEXTROROTATORY ISOMER OF ALPHA-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRID-5-YL)(2-CHLOROPHENYL) METHYL ACETATE AS THE HYDROGEN SULPHATE SALT; REGISTERED: UK EU/1/98/069/001 19980715; UK EU/1/98/069/002 19980715; UK EU/1/98/069/003 19980715 | ||||||||||||||||||||||||||
| C0036 | Belgium | ► Subscribe | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 | ||||||||||||||||||||||||||
| 90002 | Netherlands | ► Subscribe | PRODUCT NAME: CLOPIDOGREL WATERSTOFSULFAAT; REGISTRATION NO/DATE: EU 1/98/069/001 - EU 1/98/069/003 19980715 | ||||||||||||||||||||||||||
| C0036 | France | ► Subscribe | PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
Join the 21,721 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
